Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors.
暂无分享,去创建一个
Takashi Inaba | Jun-ichi Hoshi | Tomohiko Sasase | Masahiro Tanaka | T. Sasase | I. Matsuda | Masahiro Tanaka | Isamu Matsuda | Shoichi Sagawa | Fumito Shimoma | Kenji Sakoda | Masanori Shindo | J. Hoshi | T. Inaba | M. Shindo | S. Sagawa | K. Sakoda | Fumito Shimoma | Kenji Sakoda | Shoichi Sagawa
[1] M. Jirousek,et al. Synthesis of bisindolylmaleimides using a palladium catalyzed cross-coupling reaction. , 1998, Bioorganic & medicinal chemistry letters.
[2] C. Sergheraert,et al. Design and synthesis of new leads for PKC bisubstrate inhibitors. , 1994 .
[3] E. Eichler,et al. Inhibitors of glycolic acid oxidase. 4-Substituted 3-hydroxy-1H-pyrrole-2,5-dione derivatives. , 1983, Journal of medicinal chemistry.
[4] M. Faul,et al. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. , 1996, Journal of medicinal chemistry.
[5] M. Jirousek,et al. Protein kinase C inhibitors as novel anticancer drugs , 2001, Expert opinion on investigational drugs.
[6] Claudia K Derian,et al. Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3. , 2003, Bioorganic & medicinal chemistry letters.
[7] M. Saunders,et al. 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). , 2001, Bioorganic & medicinal chemistry letters.
[8] M. Faul,et al. Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. , 2003, Bioorganic & medicinal chemistry letters.
[9] J. Beijnen,et al. Protein kinase C as a target for new anti-cancer agents , 1999 .
[10] P. Davis,et al. Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. , 1992, Journal of medicinal chemistry.
[11] P. Davis,et al. Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity. , 1992, Journal of medicinal chemistry.
[12] R. Huber,et al. Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. , 1997, Structure.
[13] S. Bursell,et al. Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β Inhibitor , 1996, Science.
[14] Y. Kihara,et al. [Role of protein kinase C isozymes in cellular functions and pathological conditions]. , 2002, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.